Abiopharma

🔍 Azamian Bobak R. (Director)

Company: Tarsus Pharmaceuticals, Inc. (TARS)

Report Date: 2026-03-17

Detailed Transactions and Holdings:

• Sold 10,972 shares of Common Stock at $69.42 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 57,052.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 11,667 shares of Common Stock at $68.71 per share (Direct)
  Date: 2026-03-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 45,385.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 11,964 shares of Common Stock at $67.0 per share (Direct)
  Date: 2026-03-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 33,421.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-17 | Code: H | nature_of_ownership: By the Bobak Azamian Living Trust established April 16, 2018 | shares_owned_after: 857,991.00 | Footnotes: F2

Footnotes:

• F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
• F2: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.